New Blood-Based drug shows promise in protecting hearts after stenting
NCT ID NCT04327635
First seen Nov 11, 2025 · Last updated May 02, 2026 · Updated 21 times
Summary
This early-phase study tested the safety of a biological drug called PEP, made from donated blood, in 9 people who had just received a coronary stent. The goal was to see if PEP could prevent or reduce heart damage after the procedure. Researchers monitored for side effects and measured heart function using MRI scans.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERCUTANEOUS CORONARY INTERVENTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.